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Abstract
Mitochondria are vital organelles that coordinate cellular energy homeostasis and also have important
roles in cell death. Therefore, the removal of damaged or excessive mitochondria through autophagy, a
process called mitophagy, is critical for maintaining proper cellular function. Much of the research
elucidating the mechanism and regulation of autophagy was performed in yeast cells, so there is still a lot
of mystery surrounding how mitophagy is promoted and regulated in mammals in general and in different
tissues. The most well understood mechanism involved in mitophagy is the PINK1-PARKN pathway.
However, studies often rely on severe mitochondrial damage using CCCP that is considered nonphysiological. To find novel regulators of mitophagy in mammalian cells, we used a previously published
screen for autophagy regulators to identify the MEKK3-MEK5-ERK5 pathway as a potential regulator of
mitophagy in the absence of exogenous damage. Here, I provide evidence that genetic or
pharmacological inhibition of the MEKK3-MEK5-ERK5 pathway increases mitochondrial content by
reducing lysosome-mediated degradation of mitochondria under basal conditions. I confirm that the
MEKK3-MEK5-ERK5 pathway is not required for non-selective bulk autophagy, damage-induced
mitophagy, or restraint of mitochondrial biogenesis, confirming a selective role in basal mitochondrial
degradation. Furthermore, inhibition of MEK5 or ERK5 in erythrocytes leads to defective mitochondrial
elimination and impaired erythrocyte differentiation. In addition to finding a novel mitophagy promoting
pathway, we also worked to discover a novel mitophagy inducing compound. There are several different
mechanisms for mitophagy induction, so there is considerable interest in the field in identifying novel
chemical modulators that promote the efficient removal of mitochondria through different pathways.
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ABSTRACT
Mitochondria are vital organelles that coordinate cellular energy homeostasis and
also have important roles in cell death. Therefore, the removal of damaged or excessive
mitochondria through autophagy, a process called mitophagy, is critical for maintaining
proper cellular function.
Much of the research elucidating the mechanism and regulation of autophagy was
performed in yeast cells, so there is still a lot of mystery surrounding how mitophagy is
promoted and regulated in mammals in general and in different tissues. The most well
understood mechanism involved in mitophagy, is the PINK1-PARKN pathway.
However, studies often rely on severe mitochondrial damage using CCCP that is
considered non-physiological.
To find novel regulators of mitophagy in mammalian cells, we used a previously
published screen for autophagy regulators to identify the MEKK3-MEK5-ERK5 pathway
as a potential regulator of mitophagy in the absence of exogenous damage. Here, I
provide evidence that genetic or pharmacological inhibition of the MEKK3-MEK5ERK5 pathway increases mitochondrial content by reducing lysosome-mediated
degradation of mitochondria under basal conditions. I confirm that the MEKK3-MEK5ERK5 pathway is not required for non-selective bulk autophagy, damage-induced
mitophagy, or restraint of mitochondrial biogenesis, confirming a selective role in basal
mitochondrial degradation. Furthermore, inhibition of MEK5 or ERK5 in erythrocytes
leads to defective mitochondrial elimination and impaired erythrocyte differentiation.
In addition to finding a novel mitophagy promoting pathway, we also worked to
discover a novel mitophagy inducing compound. There are several different mechanisms
for mitophagy induction, so there is considerable interest in the field in identifying novel
chemical modulators that promote the efficient removal of mitochondria through different
pathways.
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CHAPTER 1.

INTRODUCTION

Overview of Autophagy
Discovery
The field of autophagy research began when Christian de Duve discovered
granules that were rich in hydrolytic enzymes while performing tissue fractionations on
rat livers (De Duve, Pressman, Gianetto, Wattiaux, & Appelmans, 1955; Glick, Barth, &
Macleod, 2010). He proposed that they be called lysosomes and hypothesized that they
may be involved in localized intracellular digestion (De Duve et al., 1955). De Duve later
termed the process of delivering cargo to the lysosome for digestion ‘autophagy’,
meaning ‘self-eating’ in Greek (Glick et al., 2010).
Decades later, Yoshinori Ohsumi’s laboratory used genetic screens on yeast
(Saccharomyces cerevisiae), where he identified 15 genes that were required for
autophagy (Tsukada & Ohsumi, 1993). Subsequently, most of the breakthroughs in
understanding how autophagy is regulated and executed have occurred in yeast as well.
Now, over 40 autophagy related genes (ATGs) have been identified in yeast
(Nakatogawa, Suzuki, Kamada, & Ohsumi, 2009; Wen & Klionsky, 2016). Though many
of these ATGs are conserved in other orders, including mammals, differences in how
autophagy is regulated are an active research topic (Glick et al., 2010).
Types of Autophagy
Autophagy can be divided into either chaperone mediated autophagy (CMA),
microautophagy or macroautophagy based on how the substrates are targeted and the
mechanism by which intracellular materials are delivered into the lysosome for
degradation (Khandia et al., 2019). Although these pathways are mechanistically distinct,
they all carry out degradation via the lysosome (Khandia et al., 2019). In CMA, a
chaperone protein complex targets proteins for degradation and translocated them across
the lysosomal membrane (Cuervo & Wong, 2014). Microautophagy occurs when the
lysosome, itself, invaginates and engulfs small sections of the cytoplasm (Mijaljica,
Prescott, & Devenish, 2011). Macroautophagy (here after referred to as autophagy)
occurs when a portion of cytoplasm is sequestered by a forming autophagosome before
fusing with a lysosome (Mizushima, 2007).
Molecular Mechanism of Autophagy
Autophagy can be induced by several different signaling pathways and by many
different stimuli such as nutrient depravation (Hosokawa et al., 2009), oxidative stress
(Filomeni, De Zio, & Cecconi, 2015), hypoxia (L. Liu et al., 2012), and infection
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(Khandia et al., 2019). In the presence of nutrients and cytokines, mechanistic target of
rapamycin (mTOR) blocks apoptosis and stimulates cell growth (Hosokawa et al., 2009).
On the other hand, starvation and stress inhibit mTOR which leads to autophagy initiation
(Hosokawa et al., 2009).
The first protein complex involved in autophagy induction is the autophagy
initiation complex, composed of ULK1, ATG13, FIP200, and ATG101 (Dikic & Elazar,
2018). When autophagy is initiated, ATGs are recruited to a specific location within the
cell called the phagophore assembly site (PAS) where the phagophore membrane is
nucleated by the PI3KC3 complex I (composed of VSP34, Beclin1, ATG14, AMBRA1,
and p115 (Dikic & Elazar, 2018). After nucleation, the phagophore membrane is
elongated and decorated with ATG8 family proteins such as LC3. First, free LC3 (LC3-I)
must be conjugated to the membrane bound lipid phosphatidylethanolamine (PE) to
become LC3-II (Dikic & Elazar, 2018). Conjugation of ATG8s to PE promotes
phagophore expansion and possibly has a role in sealing the phagophore into a complete
vesicle called an autophagosome (T. N. Nguyen et al., 2016). Autophagosomes then fuse
with highly acidic lysosomes that contain hydrolases which degrade any cargo inside
(Figure 1-1) (Dikic, 2017; Mizushima, 2007).
Selective versus Non-selective Autophagy
There are two major types of degradation within autophagy: selective and nonselective. In non-selective autophagy starvation triggers cytoplasmic material to be
engulfed by the autophagosome in a non-specific manner and the contents are all
degraded by the lysosome (Mizushima, 2007). Whereas in selective autophagy certain
signals can induce a highly selective targeting of specific cellular structures, such as
damaged mitochondria (mitophagy), invading bacteria (xenophagy),
misfolded/aggregated proteins (aggrephagy) as well as many other substrates (Zaffagnini
& Martens, 2016). Selective autophagy often requires cargo to be labelled with a tag for
degradation (most notably chains of ubiquitin) (Stolz, Ernst, & Dikic, 2014). These
degradation tags are then recognized by autophagy receptors that link the cargo to the
autophagic membrane via their LC3-interacting region (LIR); though some cargo
receptors are able to bind cargo directly (Kirkin, 2020; Pankiv et al., 2007). There are a
growing number of selective autophagy receptors (SARs) including NBR1, OPTN, NIX
and SQSTM1/p62 (Zaffagnini & Martens, 2016). The most well characterized example
of a SAR is p62/SQSTM1, an adaptor protein that participates in several types of
selective autophagy including mitophagy and aggrephagy.(Glick et al., 2010). Although
SARs themselves are not highly conserved, their modes of action and the signaling
cascades that activate and regulate them are (Farre & Subramani, 2016).
Furthermore, there are two forms of selective autophagy: constitutive and induced
(Mizushima, 2005). Constitutive autophagy (also known as basal autophagy) has not
been well studied, whereas induced autophagy has been much more extensively studied.
Induced autophagy can be triggered by cellular damage, dysfunctional organelles, as well
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Figure 1-1. Autophagy mechanism overview.
An expanding membrane structure (phagophore) forms a double-membrane vesicle
(autophagosome) that sequesters a portion of the cytoplasm. The autophagosome then
fuses with the lysosome, exposing its inner components to the hydrolases and highly
acidic environment in the lysosomal interior. The inner membrane of the autophagosome
is degraded along with the cargo inside. The resulting macromolecules are then released
into the cytosol for recycling.
Source: Mizushima N. Autophagy: process and function. Genes Dev. 2007;21(22):286173.
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as developmental programs (Glick et al., 2010). Basal autophagy is thought to have a
housekeeping role and acts to turn over cytosolic components such as mitochondria
(Mizushima, 2005, 2007).
Introduction to Mitophagy
The degradation of mitochondria through autophagy is known as mitophagy.
Mitophagy was first observed using electron microscopy, but it took almost 40 years for
researchers to make any breakthroughs in understanding why and how mitochondria were
being degraded (Ashford & Porter, 1962; Clark, 1957). The first sign that individual
mitochondrion could be selected for degradation came from J. J. Lemasters’ lab when
they reported that only depolarized mitochondria were sequestered by autophagosomes
(Elmore, Qian, Grissom, & Lemasters, 2001). Early insights into the mechanistic basis of
mitochondrial degradation arose from studies in yeast, when the protein ATG32 was
identified as a key mitophagy receptor (Kanki, Wang, Cao, Baba, & Klionsky, 2009;
Okamoto, Kondo-Okamoto, & Ohsumi, 2009). Around the same time, insights into
mammalian mitophagy regulation were also being made. BNIP3L/NIX was discovered to
regulate programmed mitochondrial clearance during reticulocyte maturation (Schweers
et al., 2007). Parkin was shown to have a critical role in targeting depolarized
mitochondria to be degraded (Narendra, Tanaka, Suen, & Youle, 2008). Several other
mitophagy receptors and signaling mechanisms have been discovered since, however,
there is still much left to understand about how mitophagy signaling is regulated in vivo.
Purpose of Mitophagy
Maintaining a population of healthy mitochondria is vital for proper development
and is necessary to preserve tissue and organ function in response to stress conditions
(Pickles, Vigie, & Youle, 2018). Mitochondria are well known for their importance in
metabolism and energy production, but they are also a major source of reactive oxygen
species (ROS), cytosolic DNA, and pro-apoptotic proteins (Kausar, Wang, & Cui, 2018;
McArthur et al., 2018; Murphy, 2009; West et al., 2015). Therefore, it is important to
maintain sufficient quantities of healthy mitochondria to meet current metabolic demand,
but dangerous to carry an excessive surplus of these organelles.
Damaged or dysfunctional mitochondria tend to generate higher levels of ROS
and cytosolic DNA compared to healthy mitochondria (Kausar et al., 2018; Murphy,
2009; Sliter et al., 2018). Exposure to high levels of ROS can cause DNA mutations in
both nuclear and mitochondrial DNA and can induce protein misfolding throughout the
cell (Kausar et al., 2018; Murphy, 2009). Mutations in mitochondrial DNA further
decrease the health of the mitochondrial population and promote additional ROS
production (Hahn & Zuryn, 2019; Mattiazzi et al., 2004; Nissanka & Moraes, 2018).
There are other situations in which mitochondrial content changes even in the absence of
damage, such as during differentiation of highly specialized cell types or induction of a
metabolic shift towards a glycolytic phenotype or an oxidative phosphorylation

4

phenotype (Esteban-Martinez & Boya, 2018; Esteban-Martinez et al., 2017; Hu et al.,
2016; Palikaras, Lionaki, & Tavernarakis, 2018) Thus to maintain homeostasis, the cell
has evolved complex systems for the quality control of mitochondria (Ding & Yin, 2012).
These systems are designed to balance the elimination of dysfunctional or superfluous
mitochondria with mitochondrial biogenesis (Pickles et al., 2018)..
Mechanisms of Mitophagy
In mammals, mitophagy is induced by a variety of cellular stimuli, including
cellular differentiation; hypoxic conditions; mitochondrial damage; and paternal
mitochondrial elimination (Pickles et al., 2018). Interestingly, several different molecules
and mechanisms are utilized in mitophagy depending on the needs of the cell (Figure
1-2).
PINK1/Parkin pathway
The most well studied mechanism for targeting damaged mitochondria for
elimination in metazoans, such as C. elegans and mammals, usually involves two
proteins: PINK1, a kinase that constitutively localizes to the mitochondria and Parkin, a
cytosolic E3 ubiquitin ligase. When mitochondria are healthy and have a strong
membrane potential, PINK1 is imported into the mitochondria through the outer
mitochondrial membrane and then the inner mitochondrial membrane (Jin et al., 2010).
While passing through the inner membrane, PINK1 is cleaved by the proteases in the
mitochondrial matrix (MPP and PARL) (Jin et al., 2010). The cleavage product is then
released into the cytoplasm and degraded (Pickles et al., 2018). However, mitochondria
with low membrane potential cannot successfully import PINK1 past the mitochondrial
inner membrane, preventing PINK1 from being cleaved (Jin et al., 2010). This causes
PINK1 to accumulate on the surface of the mitochondria. PINK1 can then form dimers
and auto-phosphorylate (Okatsu et al., 2013). PINK1 kinase activity is necessary and
sufficient for the recruitment of Parkin to mitochondria (Lazarou, Jin, Kane, & Youle,
2012). In addition to auto-phosphorylation, PINK1 also phosphorylates Parkin to increase
its E3-ligase activity, allowing it to ubiquitinate substrates (Lazarou et al., 2012; ShibaFukushima et al., 2012). PINK1 can then phosphorylate the ubiquitin at Ser65, which
causes a structural change in ubiquitin and makes it resistant to deubiquitinating enzymes
(Shiba-Fukushima et al., 2012). Polyubiquitin chains act as an “eat me” signal for
damages organelles, so deubiquitinating enzymes, such as USP15 and USP30, inhibit
mitophagy by removing the ubiquitin chains from the mitochondrial surface (Palikaras et
al., 2018). Though this pathway has been very well characterized, most studies depend on
ectopic Parkin overexpression and mitochondrial depolarization with CCCP or other
pharmacological agents (Drake, Springer, Poole, Kim, & Macleod, 2017; Lazarou et al.,
2015; Narendra et al., 2008). Additionally, endogenous Parkin is poorly expressed in
several mammalian tissues and cell lines, so more work is needed to elucidate how
mitophagy is regulated in those tissues (Huynh, Dy, Nguyen, Kiehl, & Pulst, 2001;
McWilliams et al., 2018).

5

Figure 1-2. Mechanisms of mitophagy.
Polyubiquitinated proteins are recognized by SARs, including p62, OPTN, and NDP52.
SARs recognize and bind LC3 to promote autophagosome formation. PINK1
accumulates on the surface of mitochondria with low membrane potential. PINK1
recruits Parkin by phosphorylating both Parkin and ubiquitin. Parkin then
polyubiquitinates OMM proteins such as VDAC1 and MFN1/2. Receptor-mediated
mitophagy also utilizes various OMM proteins such as BNIP3, NIX, and FUNDC1. In
addition, PHB2 can also act as an inner mitochondrial membrane receptor in cases where
the mitochondrial membranes rupture and PHB2 is exposed to the cytosol where it can
bind LC3.
Source: Palikaras K, Lionaki E, Tavernarakis N. Mechanisms of mitophagy in cellular
homeostasis, physiology and pathology. Nat Cell Biol. 2018;20(9):1013-22.
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Non-parkin ubiquitination
In addition to Parkin, there are several other E3 ligases, such as SMURF1, MUL1
and ARIH1, that also regulate mitophagy through ubiquitination (Palikaras et al., 2018).
They are recruited to the mitochondrial outer membrane where they create ubiquitin
chains, allowing autophagy adaptor proteins, including optineurin (OPTN), nuclear dot
protein 52 (NDP52), NBR1 and p62, to bind (Yoo & Jung, 2018). Core autophagy
proteins are then recruited to mediate phagophore biogenesis and autophagosomal
membrane expansion (Palikaras et al., 2018). The serine/threonine-protein kinase TBK1
(TANK binding kinase 1) can phosphorylate mitophagy adaptors like OPTN, NDP52 and
p62 to enhances their ability to bind to ubiquitin chains, promoting mitochondrial
removal (Richter et al., 2016). Several studies have shown that p62 is not required for
mitophagy to take place (Narendra, Kane, Hauser, Fearnley, & Youle, 2010). Therefore,
the importance and function of p62 in mitophagy is controversial and requires further
investigation into cell type- and tissue-specific contexts.
Mitochondrial proteins as mitophagy receptors
In addition to ubiquitin dependent mitophagy, some outer mitochondrial
membrane proteins like NIX, BNIP3, and FUNDC1 also act as mitophagy receptors,
targeting mitochondria directly to autophagosomes for degradation. NIX has been
reported to interact with ATG8 family members GABARAP and LC3 through this LIR
domain, although the role of this interaction has been contested (Novak et al., 2010).
BNIP3 is about 50% homologous to Nix and also acts as a mitophagy receptor (Pickles et
al., 2018). Nix and BNIP3 are both reported to have roles in hypoxia induced mitophagy,
and protein levels for both are transcriptionally increased under hypoxic conditions
(Palikaras et al., 2018). BNIP3 has additional roles in promoting the fission of damaged
mitochondria by recruiting mitochondrial fission protein Drp1 to the outer mitochondrial
membrane (Y. Lee, Lee, Hanna, & Gustafsson, 2011). There is also evidence of cross talk
between PINK1/Parkin mitophagy and both BNIP3 and Nix mediated mitophagy. BNIP3
increases PINK1 stability on the mitochondrial surface by inhibiting its cleavage, and Nix
is a Parkin ubiquitination substrate (Gao et al., 2015; T. Zhang et al., 2016). FUNDC1 is
another outer mitochondrial membrane protein that promotes mitophagy during hypoxia
(Yoo & Jung, 2018). Under normoxic conditions, FUNDC1’s LIR motif is kept inactive
by phosphorylation at Ser13 and Tyr18 (Chen et al., 2014; L. Liu et al., 2012). Under
hypoxic conditions, FUNDC1 is dephosphorylated at Ser13 by PGAM5 and
phosphorylated by ULK1 at Ser17 which allows the LIR motif to interact with LC3
(Chen et al., 2014). Proteins in the inner mitochondrial membrane can also act as
mitophagy receptors. Prohibitin2 (PHB2) is a protein in the inner mitochondrial
membrane that has been shown to mediate Parkin-dependent mitophagy (Wei, Chiang,
Sumpter, Mishra, & Levine, 2017). When the mitochondrial membrane is depolarized
and the outer membrane ruptures, PHB2 becomes exposed to the cytoplasm where it can
associate with LC3 and p62 to generate a phagophore (Wei et al., 2017; Xiao, Zhou, Lu,
Zhou, & Cai, 2018).
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Mitophagy in Development and Disease
Reticulocyte maturation
In addition to its role in removing damaged mitochondria, mitophagy must also
remove perfect healthy mitochondria during key stage in development (Gustafsson &
Dorn, 2019). In most mammals, mitochondria are absent from mature red blood cells
(Mortensen et al., 2010). During late stages of hematopoietic stem cell differentiation,
reticulocytes (enucleated immature red blood cells) must lose their mitochondria to
become mature erythrocytes (Mortensen et al., 2010). Nix protein levels are increased on
the surface of the mitochondria during the transition from reticulocyte to erythrocyte
(Aerbajinai, Giattina, Lee, Raffeld, & Miller, 2003), and mature red blood cells from NIX
knockout mice have increased mitochondrial content (Schweers et al., 2007).
Interestingly, mitochondrial clearance in reticulocytes does not occur through the
canonical ATG5/ATG7 autophagy pathway (Honda et al., 2014). However, it has been
shown that mitochondrial clearance is dependent on Ulk1, as murine reticulocytes
lacking Ulk1 have an impaired ability to clear mitochondria (Kundu et al., 2008).
Clearance of paternal mitochondria
In most animals, from flies and worms to mice and humans, mitochondrial DNA
(mtDNA) is only inherited maternally. It was unknown whether paternal mtDNA was lost
due to dilution, as there is a relatively small number of mitochondria in sperm cells or if
paternal mitochondria were actively targeted for degradation. Deep sequencing has found
no residual amounts of paternal mtDNA in most cases, indicating that paternal
mitochondria are likely actively eliminated. Mice engineered to possess a mixture of two
different sets of mtDNA had abnormal metabolism, decreased cognitive function, and
increased stress, providing evidence for why evolution has favored single parent
inheritance (Sharpley et al., 2012). There is conflicting evidence for whether autophagy
mediates paternal mtDNA elimination in mammals (Luo et al., 2013; Sutovsky et al.,
2000). In fertilized oocytes, p62, GABARAP and VCP (shown to be essential for
PINK1/Parkin mitophagy (Kim et al., 2013)) quickly aggregate around sperm
mitochondria, and inhibition of either p62 or VCP delays the removal of sperm
mitochondria (Song, Yi, Sutovsky, Meyers, & Sutovsky, 2016). Knocking down p62,
PINK1, or the mitochondrial fission protein, Fis1, in mouse embryos resulted in impaired
paternal mitochondrial removal (Rojansky, Cha, & Chan, 2016). When mitochondrial E3
ligases, Parkin and Mul1, were both knocked down embryos also retained paternal
mitochondria (Rojansky et al., 2016). All together, these studies indicate that autophagy
and, more specifically, mitophagy-related proteins have an important role in paternal
mtDNA elimination.
Stem cell maintenance
Interestingly, the metabolic status of embryonic stem cells has a key role in
maintaining stemness as well as differentiation (Gustafsson & Dorn, 2019). Generating
pluripotent stem cell using somatic cell reprogramming involves an initial increase in
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mitochondrial content followed by a decrease that relies upon Nix-dependent mitophagy
(Palikaras et al., 2018). Additionally, loss of PINK1-dependent mitophagy resulted in
dramatically decreased efficiency of induced pluripotent stem cell reprogramming and
altered metabolism (Vazquez-Martin et al., 2016). Induced pluripotent stem cells (iPSCs)
are highly glycolytic and contain few mitochondria which are small and rounded with
condensed cristae and the low membrane potential (Palikaras et al., 2018). Conversely,
differentiation induces mitochondria to become long and tubular in shape, mitochondrial
mass increases, and cellular metabolism switches to OXPHOS (Vazquez-Martin et al.,
2016). Mitophagy-deficient iPSCs have attenuated glycolysis and contain a mixture of
mature and immature mitochondria (Vazquez-Martin et al., 2016). Mitophagy-deficient
iPSC colonies also tend to spontaneously differentiate and form heterogeneous
populations of cells (Vazquez-Martin et al., 2016).
Cardiovascular health
Mitophagy is important for both cardio myocyte maturation as well as
mitochondrial maintenance in adult heart cells. Fetal mitochondria primarily use glucose
for ATP production, while adult heart cells have far greater metabolic demands, so they
utilize fatty acids for ATP production (Palikaras et al., 2018). During the maturation
process, PINK1, Parkin, and mitochondrial fusion protein MFN2 act together to eliminate
fetal mitochondria (Palikaras et al., 2018). In fact, cardiac specific deletion of Parkin
during the metabolic remodeling process is lethal due to disruption of mitochondrial
maturation and retention of fetal mitochondria in myocytes (Gustafsson & Dorn, 2019).
Mitophagy continues to play an important role in the maintenance of the adult
cardiovascular system. The human heart is highly metabolically active organ (Gustafsson
& Dorn, 2019). Mitochondrial function and impaired mitophagy strongly influence
cardiac function and have been implicated in several cardiomyopathies (Palikaras et al.,
2018). PINK1 protein levels are significantly reduced in end-stage heart failure in
humans (Billia et al., 2011). Cardiomyocytes of PINK1 null mice have altered
mitochondrial morphology, increased mitochondrial content, and elevated ROS levels
(Billia et al., 2011). PINK1 null mice also exhibit pathological cardiac hypertrophy and
ventricular dysfunction (Billia et al., 2011). Additionally, myocytes activate mitophagy
after ischemia to clear damaged mitochondria before they cause harm to the cell
(Hamacher-Brady et al., 2007). Studies have also shown that impaired mitophagy in
cardiomyoctes leads to increased susceptibility to stress and heart failure (Ikeda et al.,
2015; Kubli et al., 2013).
Neurodegenerative diseases
Parkinson’s disease (PD) is a neurodegenerative disorder characterized motor
symptoms such as tremors. PD is caused by the loss of dopaminergic (DA) neurons in a
region of the brain called the substantia nigra, (Airavaara et al., 2020). Mitochondrial
dysfunction has been implicated in studies of sporadic, familial, and pharmacologically
induced forms of PD (Gao et al., 2017). Additionally, loss-of-function mutations in
PINK1 and Parkin have been identified in hereditary PD, and mutation in PINK1/Parkin
homologues cause Parkinson’s like symptoms in flies (Greene et al., 2003; Y. Yang et al.,
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2006). On the other hand, Parkin and PINK1 perturbations do not phenocopy clinical PD
in mice (Blesa & Przedborski, 2014). However, POLG mutator mice that also lack Parkin
do show a decrease in DA neurons (Pickrell et al., 2015). POLG mutator mice
accumulate dysfunctional mitochondria due to proofreading deficiency in a DNA
polymerase which causes an increase in mtDNA mutations (Trifunovic et al., 2004).
More work needs to be done to elucidate how impaired PINK1 and Parkin signaling
contribute to the development of PD and if they have roles maintaining mitochondrial
health outside of mitophagy.
Cancer
The role of mitophagy in cancer progression is still controversial and appears to
depend on cancer type. Studies have shown a correlation between impaired Parkin
activity in many kinds of cancer such as glioblastoma, breast cancer, and ovarian cancer
(Denison et al., 2003; Shah et al., 2012; Veeriah et al., 2010). Parkin knockout mice have
been shown to develop hepatocellular carcinoma and have increased vulnerability to
gamma irradiation induced tumorigenesis (Fujiwara et al., 2008; C. Zhang et al., 2011).
However, whether Parkin’s tumor suppression properties are due to Parkin’s role in
mitophagy has yet to be shown. It has been proposed that by eliminating dysfunctional
mitochondria, mitophagy may be reducing oxidative damage and suppressing initiation of
cancer (Gustafsson & Dorn, 2019).
Mitochondrial Turnover
Mitochondrial turnover refers to the process of old, damaged, or dysfunction
mitochondria or subsets of mitochondrial proteins being eliminated and then replaced
with new mitochondria. Mitophagy is only one of several quality control mechanisms for
mitochondria. Other methods include proteases in the mitochondrial matrix and inner
membrane space, proteasome-dependent degradation of mitochondrial proteins, and the
mitochondrial unfolded protein response (Pickles et al., 2018). In order to balance
mitochondrial elimination, mitochondrial biogenesis is needed. Mitochondria have their
own separate genomes that must act in coordination with the nuclear genome in order to
produce new mitochondria. PGC1α, considered to be the master mitochondrial biogenesis
transcription factor, stimulates NRF1 and NRF2 gene expression in the nucleus
(Scarpulla, 2011). NRF1 and NRF2 activate the transcription of nuclear encoded
mitochondrial proteins including the protein import machinery, the co-factors for
respiratory chain complex assembly, and the mitochondrial DNA transcription and
translation regulatory factors, including mitochondrial transcription factor A (Tfam)
(Gleyzer, Vercauteren, & Scarpulla, 2005). Tfam is required for mitochondrial gene
transcription and for regulating mtDNA copy number (Scarpulla, 2011).
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MEKK3-MEK5-ERK5 Kinase Cascade
MEK5 and ERK5 kinases are part of a family called the mitogen-activated protein
kinases (MAPKs) are which are a group of highly conserved enzymes that are expressed
in all eukaryotic cells and mediate several different intracellular processes such as
growth, differentiation, and apoptosis (Drew, Burow, & Beckman, 2012). MAPK
pathways are three-tiered kinase cascades (Figure 1-3). Kinases at the top of the cascade
are referred to as the MAPK kinase kinase (MAPKKK). MAPKKKs are often stimulated
by extracellular stimuli like growth factors (Nithianandarajah-Jones, Wilm, Goldring,
Muller, & Cross, 2012). The MAPKKK then phosphorylates and activates the
downstream kinase, the MAPK kinase (MAPKK) on specific serine and threonine
residues (Nithianandarajah-Jones et al., 2012). The MAPKK then activates the final
member of the cascade, the MAPK, by phosphorylating the threonine and tyrosine
residues of the T-X-Y motif which is common among all MAPKs (NithianandarajahJones et al., 2012). Once the final MAPK has been activated, it can then phosphorylate
and modify the behavior of its downstream effector molecules. In mammals there are
distinct subfamilies of MAPKs such as the ERK 1/2 cascade, the ERK5 cascade, the JNK
1/2/3 cascade, and the p38 proteins, (Drew et al., 2012). ERK5 is the most recently
identified MAPK and regulates a variety of cellular processes including cell survival,
proliferation, migration, and angiogenesis (Drew et al., 2012).
ERK5 was discovered in 1995 by two separate groups. J. Dixon’s group first
identified ERK5’s upstream kinase, MEK5, and used a yeast two-hybrid screen to
discover ERK5 (G. Zhou, Bao, & Dixon, 1995). J. Han’s group used PCR to identify a
novel MAPK gene in a human placenta cDNA library, which they named Big MAPK 1
(BMK1) as it is much larger in size compared to ERK1/2 (J. D. Lee, Ulevitch, & Han,
1995). ERK5 and BMK1 were found to be the same protein. Together the groups showed
that ERK5 is abundantly expressed in the heart, skeletal muscle, placenta, lungs and
kidneys (J. D. Lee et al., 1995; G. Zhou et al., 1995). It was later shown that ERK5 is
ubiquitously expressed in a variety of tissues and cell lines and is present in both nuclear
and cytoplasmic compartments.(Nithianandarajah-Jones et al., 2012)
Compared to the other MAPKs, ERK5 has an elongated C-terminal tail that is
over 400 amino acids long, making it over twice the molecular weight of many other
MAPKs (G. Zhou et al., 1995). Within the C-terminal domain there is a nuclear
localization signal (NLS) domain which allows ERK5 to translocate to the nucleus two
proline-rich (PR) domains which are thought to be binding sites for SH3-domaincontaining proteins, a MEF2-interacting region, and transcriptional activation domain
(TAD) (Nithianandarajah-Jones et al., 2012). The TAD can be autophosphorylated
allowing ERK5 to directly regulate gene transcription, which is a unique ability
compared to conventional MAPKs (Nishimoto & Nishida, 2006).
In ERK5’s inactive and unphosphorylated state, there is an interaction between
the N and C terminals that holds ERK5 in a folded conformation (Nithianandarajah-Jones
et al., 2012). This interaction prevents NLS signaling and may also signal for nuclear
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Figure 1-3. MAPK signaling cascade.
Mammalian cells have four MAPK signaling cascades: ERK1/2, ERK5, p38 MAPKs and
JNK 1/2/3, that are organized into a system with three tiers known as a MAPK module.
Stimuli such as cytokines, growth factors, and environmental stresses activate various
MAPK cascades. First, the apical MAPKKK is phosphorylated and activated, allowing it
to activate the downstream MAPKK. The MAPKK then dual phosphorylates specific
threonine (T) and tyrosine (Y) of the T–X–Y motif present within the kinase domain of
the MAPK. There are a variety of downstream cytosolic or nuclear substrates of the
MAPK signaling cascade, including other protein kinases such as p90 and SGK and
transcription factors such as MEF2C and Elk-1.
Source: Nithianandarajah-Jones GN, Wilm B, Goldring CE, Muller J, Cross MJ. ERK5:
structure, regulation and function. Cell Signal. 2012;24(11):2187-96.
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export, sequestering inactive ERK5 to the cytoplasm (Nithianandarajah-Jones et al.,
2012). Activation by MEK5 induces a conformational change in ERK5, exposing the
NLS, and allowing ERK5 to translocate into the nucleus (Drew et al., 2012). Nuclear
localization is crucial for ERK5’s role in transcriptional activation and cell proliferation
(Gomez, Erazo, & Lizcano, 2016). While the best characterized ERK5 substrates are
nuclear transcription factors such as c-FOS, c-MYC, and MEF2 family transcription
factors, ERK5 does have a few cytosolic substrates including p90RSK kinases, the proapoptotic protein BAD, and the GAP junctional protein CX43 (Drew et al., 2012; Gomez
et al., 2016). However, while it has been shown that inhibiting ERK5 reduces
phosphorylation of these substrates, only CX43 has been confirmed to be directly
phosphorylated by ERK5 (Tubita, Lombardi, Tusa, Dello Sbarba, & Rovida, 2020).
ERK5 is ubiquitously expressed in mammalian tissues and is activated by
extracellular signals such as growth factors, several cellular stressors, and oxidative
phosphorylation (Khan et al., 2018; Nishimoto & Nishida, 2006; Nithianandarajah-Jones
et al., 2012). Mouse genetic studies have demonstrated that MEKK2/3-MEK5-ERK5
signaling is required for early embryogenesis, development of the vasculature and
muscles, endothelial cell function, and cardio protection (Hayashi et al., 2004; W. Liu et
al., 2017; Nishimoto & Nishida, 2006; Nithianandarajah-Jones et al., 2012). Alterations
in the MEKK2/3-MEK5-ERK5 pathway have been associated with several human
diseases and disorders including cancer, childhood obesity, scoliosis, and cerebral
cavernous malformation (Cullere, Plovie, Bennett, MacRae, & Mayadas, 2015; Simoes,
Rodrigues, & Borralho, 2016; T. Zhou et al., 2018; Zhu et al., 2014)
Summary and Aims
Cells need to maintain sufficient quantities of healthy mitochondria to meet their
metabolic demands, but it can be dangerous for cells to carry too many of these
organelles. Mitophagy is essential to maintaining a population of healthy mitochondria
and is needed for proper development and is necessary to preserve tissue and organ
function in response to a variety of stressors (Pickles et al., 2018). Research in mitophagy
has become very popular in recent years, and it is becoming clear that mitophagy is a
complex cellular response that depends on several factors such as tissue type, cellular
metabolic status, type of stressor, and signaling contexts. However, there is still a lot to
learn about its physiological regulation and how mitophagy contributes to diseases.
In this study, I utilized a variety of methods to investigate the role of the MEKK3MEK5-ERK5 signaling cascade in basal mitochondrial degradation in mammalian cells
and in erythrocyte maturation. I also explored using novel natural products to induce
mitophagy. These results will potentially shed light on important biological mechanisms,
therapy development, and drug design for targeting modulation of the autophagy
pathway.

13

CHAPTER 2.

MATERIALS AND METHODS
Cell Culture

Transformed MEFs, U2OS cells stably expressing mitochondrial targeted
mCherry, and GFP-LC3B, and HeLa YFP-Parkin cells were received from Michael
White’s laboratory. The U2OS GFP-LC3B cells were originally a kind gift from
Xiaodong Wang, and the HeLa YFP-Parkin cells were originally a kind gift from Richard
Youle. Cells were grown in DMEM supplemented with 10% FBS, L-Glutamine,
Penicillin and Streptomycin, and Sodium Pyruvate, and incubated at 37o C and 5% CO.
Mito-mCherry, GFP-LC3B, and mito-mKeima expressing U2OS cells were maintained
in 1 mg/ml G418 DMEM media.
Transfection
Overexpression
Plasmid transfections were performed using Effectene (QIAGEN) according to
the manufacturer’s protocol. Mito-mKeima stably expressing parental and ERK5 KO
U2OS cells were transfected with addgene #56018, selected with 1mg/ml G418 for 2
weeks, and flow sorted for high expressers.
Knockdown
Knockdown experiments for figure 3-3 were performed as described in Potts et al.
2013, but briefly HCT116 cells were transfected using Dharmafect 4 and Thermo Fisher
Scientific's human siARRAY® library SMARTpools and miRNA mimics was based on
the Wet Reverse Transfection Version 2.0 protocol.
All other knockdown experiments were performed using Lipofectamine
RNAIMAX (Invitrogen) according to the manufacturer’s protocol and with the following
siRNA constructs obtained from Sigma: MISSION siRNA Universal Negative Control #1
(SIC001), SQSTM1/P62 (SASI_Hs01_00118616, SASI_Hs01_00118618,
SASI_Hs01_00118620, SASI_Hs01_00118621), MAP3K3/MEKK3
(SASI_Hs01_00047592, SASI_Hs01_00047591, SASI_Hs01_00047590,
SASI_Hs01_00047593) , MAP2K5/MEK5 (SASI_Hs01_00115610,
SASI_Hs01_00115609, SASI_Hs01_00115611, SASI_Hs02_00334374), MAPK7/ERK5
(SASI_Hs01_00226859, SASI_Hs01_00226860, SASI_Hs01_00226861,
SASI_Hs01_00226862). siRNA pools indicate that all of the oligos from the specified
gene were mixed together in equal quantities before being added to cells.
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CRISPR/Cas-9 Targeting ERK5
All CRISPR/Cas-9 knockouts were kindly provided by collaborators Shondra
Miller and Sadie Sakurada. SQSTM1/p62 and MAPK7/ERK5 knockout U2OS cells were
generated using CRISPR-Cas9 technology. Briefly, 400,000 U2OS cells were transiently
transfected with precomplexed ribonuclear proteins (RNPs) consisting of 100 pmol of
chemically modified sgRNA (sgSQSTM1 5’ - gagggaaagggcuugcaccg -3’ or sgMAPK7
5’ – agacggcgaggacggcucug - 3’, Synthego) 35 pmol of Cas9 protein (St. Jude Protein
Production Core), and 200ng of pMaxGFP (Lonza) via nucleofection (Lonza, 4DNucleofector™ X-unit) using solution P3 and program CM-104 in a small (20ul) cuvette
according to the manufacturer’s recommended protocol.
Five days post nucleofection, cells were single-cell sorted by FACS to enrich for
GFP+ (transfected) cells, clonally selected, and verified for the desired targeted
modification via targeted deep sequencing using gene specific primers with partial
Illumina adapter overhangs (hSQSTM1.F – 5’ - acagccccacagtgacgacagaggg - 3’ and
hSQSTM1.R 5’- tgggggaggaattagcagagcggca -3’ or hMAPK7.F – 5’
agctagtctgccacgaaccagccgc 3’ and hERK5.R – 5’ cgggcggaggacaccactccatagg 3’,
overhangs not shown). NGS analysis of clones was performed using CRIS.py (Connelly
& Pruett-Miller, 2019). Three MAPK7/ERK5 knockout clones were identified, and
genotypes are given below. SQSTM1/p62 knockout clone genotypes are available upon
request.
WT

5’- aggaagacggcgaggacggctctgcggagccccccgggcccgtgaagg -3’

ERK5 KO Clones
1
-28bp 5’- aggaagacggc----------------------------ccgtgaagg -3’
+1bp 5’- aggaagacggcgaggacggctTctgcggagccccccgggcccgtgaagg -3’
2

+1bp 5’- aggaagacggcgaggacggctTctgcggagccccccgggcccgtgaagg -3’
-4bp 5’- AGGAAGACGGCGAGGA---TCTGCGGAGCCCCCCGGGCCCGTGAAGG -3’
3

+1bp 5’- aggaagacggcgaggacggctTctgcggagccccccgggcccgtgaagg -3’
+2bp 5’- aggaagacggcgaggacggctctCTgcggagccccccgggcccgtgaagg -3’
Drug Treatments

Unless otherwise stated cells were treated with 10uM BIX02189 (Tocris 4842)
and 10uM XMD8-92 (Tocris 4132) for 16 hours and 50nM Bafilomycin A1 (Sigma
B1793) for 2 hours.
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Mito-mCherry Mitochondrial Content
U2OS cells stably expressing mito-mCherry were plated in 6-well plates for flow
cytometry analysis or in Nunc Lab-Tek II chambered coverglass for microscopy imaging.
The cells were stained with 100nM Mito-Tracker Green FM for 30 minutes then washed
with PBS three times. After the final PBS wash, cells are treated with either a DMSO
control, BIX02189, or XMD8-92. Cell were then incubated for 16-24 hours and
trypsinized and resuspended in Flow buffer for Flow Cytometry analysis on a BD
Biosciences Fortessa or continually imaged on Multimodal 3i Marianas, then analyzed
for relative fluorescence of Mito-Tracker Green FM compared to mito-mCherry.
Mitochondrial Uncoupling
HeLa YFP-Parkin cells were treated with 10 nM CCCP overnight in addition to
indicated treatments. Cells were then fixed and stained with DAPI and TOMM20
antibody.
U20S parental and ERK5 KO U2OS cells expressing mito-mKeima were treated
with 10 nM CCCP overnight in addition to indicated treatments. Cells were then analyzed
via flow cytometry.
Confocal Imaging
Images were taken with Leica SP8 TCS equipped with White Light Laser, 405 nm
diode laser using 63x/1.4NA/Oil/HC PL APO CS2/0.14mm objective confocal
microscope. Mito-mCherry images were created from an over-sampled Z-stack with XY
pixel size of 16 nm and Z-step size of 100 nm. For higher resolution images
deconvolution was performed in Huygens Professional 16.10 (Scientific Volume
Imaging, Netherlands). Isosurface rendered image was created in Imaris 9.3 (Oxford
Instruments, UK).
GFP-LC3 puncta and SQSTM1/p62 puncta were manually counted on a per cell
basis.
ERK5+/+ and ERK5 -/- U2OS cells stably expressing mitochondrial targeted
mKeima were plated in Nunc Lab-Tek II chambered coverglass and imaged live on the
Leica SP8 TCS confocal microscope. Data were analyzed by comparing 561 (acidic)
signal to 458 (neutral) signal (Figure 2-1).
Lysosomal Content and Acidification
Lysosomal content was determined by staining with LysoTracker Red DND-99
(L7528) at 100nM for 30 minutes. Lysosomal acidification was determined by staining
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Figure 2-1. Mitochondrial targeted mKeima detects mitophagy events.
Keima is a fluorescent protein that has dual-excitation and is pH sensitive. Keima is also
resistant to degradation by lysosomal proteases, making it ideal for use in autophagy
research. Within the mitochondria (pH 8.0is predominately excited by 440nm. Within the
acidic lysosome (pH 4.5), Keima’s excitation shifts to a longer-wavelength excitation,
586nm. Keima is a fluorescent protein with an excitation spectrum that changes
according to pH. Thus, when Keima is targeted to the mitochondria, the ratio of
fluorescent intensity in neutral vs acidic conditions can be used to determine the level of
mitophagy in living cells.
Source: Sun N, Malide D, Liu J, Rovira, II, Combs CA, Finkel T. A fluorescence-based
imaging method to measure in vitro and in vivo mitophagy using mt-Keima. Nat Protoc.
2017;12(8):1576-87.
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with LysoSensor Green DND-189 (L7528) at 1mM for 10 minutes. Cells were then
imaged using a BioTek Cytation 5 Cell Imaging Multi-Mode Reader. Cells were imaged
using 20x objective. Signal was analyzed via relative fluorescence using Cell Profiler
(McQuin et al., 2018).
Flow Cytometry
Cells were treated as indicated, trypsinized, spun down at 400 rpm, and
resuspended in buffer made from 1 x PBS, 2% serum, 1 mM EDTA, and 0.1% Sodum
Azide. Cells were stained with DAPI. Fluorescence was then quantified on a BD
Biosciences Fortessa by gating on single live cells and subsequently analyzed using FloJo
v10.6.2.
Immunoblotting
Western blots were performed by lysing cells in 6x Laemmli loading buffer (10%
SDS, 20% glycerol, 5% β-mercaptoethanol, 15% 1M Tris pH6.7, 2mg/ml bromophenol
blue) separated on polyacrylamide gels, transferred to PVDF membranes and probed with
antibodies against p62/SQSTM1 (CS 51145), XPB (SC-293), TOMM40 (MBL 3740), Bactin (Sigma A1978), VDAC (CS 4867S), S6K (CS 9202S), ERK5 (CS 3372S),
mtCOX2 (Ab797393), MEKK3 (SC-28769), MEK5 (Invitrogen PA5-15083), PGC1α
(CS 2178S), pERK5 (CS 3371S).
RNAseq
RNA was extracted from cultured cells using RNeasy Kit (QIAGEN #74104)
following manufacturers’ protocols. RNA concentration was measured using a NanoDrop
(Thermo Fisher scientific, Waltham, MA) and the quality of RNA was determined with a
bioanalyzer (Agilent Technologies, Santa Clara, CA). Libraries were prepared using the
TruSeq Stranded Total RNA Library Prep Kit (Illumina, San Diego, CA) and subjected to
100 cycle paired-end sequencing on the Illumina HiSeq platform.
Promega Autophagy Assay
HEK293 autophagy reporter cells (HiBiT-HaloTag-LC3, Promega #GA1040)
were grown in in DMEM (ThermoFisher #31053-028) supplemented with 10% FBS
(Hyclone #SH30071), L-Glutamine (ThermoFisher #25030-081), Penicillin and
Streptomycin (ThermoFisher #15140-122), Sodium Pyruvate (ThermoFisher #11360070), and 500 µg/mL G418 (ThermoFisher #10131) at 37o C and 5% CO2. 2500 cells in
25 µl of G418-free media were plated into each well of Corning 8804BC 384-well plates
and grown for 18 hours. Cells were then treated with 10-point curves with 3-fold
dilutions and a top concentration of 60 µM of Bafilomycin A1 (positive control for
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autophagy inhibition), Rapamycin (TOCRIS #1292; positive control for autophagy
activation), BIX02188, BIX02189, and XMD8-92, or DMSO using a V&P Scientific
S100 pin-tool before they were returned to 37°C with 5% CO2 for 24 hours. The assay
plates were then equilibrated to room temperature for 15 minutes before the addition of
25 µl of Nano-Glo HiBiT Lytic Detection System (Promega #N3030.) The plates were
then shaken at 300 rpm for 2 minutes on an orbital shaker, incubated for 30 minutes at
room temperature, and the luminescence of each well measured using a Perkin Elmer
Envision plate reader.
Erythroblast maturation
Ter119-negative erythroid progenitors were isolated from embryonic day 13.5 or
14.5 Balb/c murine fetal livers as described (Sulahian, Cleaver, & Huang, 2009). The
purity of the cells was confirmed by staining cells with PE-CD71 and allophycocyanin
(APC)-Ter119 antibodies (all from BD Biosciences) by flow cytometry. Approximately
10% of total fetal livers were purified as Ter119 negative. These progenitors were set up
on retronectin coated plates for differentiation and were followed over three days for
differentiation status and mitochondrial content. The data were acquired on a BD
FACSCalibur and analyzed by FlowJo 8.8.4. To measure mitochondrial content, cells
were stained with 25nM MitoTracker Deep Red FM (Molecular Probes, Invitrogen) for
30 min at 37°C.
For inhibitor treatments starting on Day 0, Ter119-negative progenitors were set
up for differentiation directly after purification in erythropoietin (Epo) media in the
presence of inhibitor on retronectin coated plates. For inhibitor treatments starting on Day
2 and Day 3 Ter119-negative progenitors, 20 hours after culturing in Epo medium or 1
day after removal from EPO medium, were set up for differentiation separately, and
inhibitors were added when indicated. Erythroid differentiation was monitored on days 1,
2 and 3 with PE-CD71 (BD Biosciences) and APC-Ter119 (eBioscience) by flow
cytometry. 7-AAD (BD Biosciences) staining was used to exclude dead cells. Cells were
treated with DMSO, 10 µM BIX02188, or 10 µm XMD8-92.
Statistical Analysis
Statistical analyses were performed using Graphpad Prism 8; significance was
assessed by 2-tailed Student’s t-test or by 1- or 2-factor ANOVA analysis.
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CHAPTER 3.

MEKK3-MEK5-ERK5 SIGNALING PROMOTES
MITOCHONDRIAL DEGRADATION

SQSTM1/p62 Constitutively Delivers Mitochondria to Lysosomes for Degradation
in the Absence of Exogenous Damage
The primary question I set out to address is what controls basal mitochondrial
degradation in the absence of exogenous damage. This process is known to be
mechanistically distinct from damage-induced mitophagy, which requires the kinase
PINK1, the E3 ligase Parkin, and the selective autophagy receptors NDP52 and
Optineurin (Lazarou et al., 2015; McWilliams et al., 2018). We first investigated whether
an alternative selective autophagy receptor, SQSTM1/p62, supports mitochondrial
degradation in the absence of exogenous damage. We selected p62 as an initial candidate
because it is not required for damage-induced, Parkin-dependent mitophagy but has been
reported to be important for mitochondrial degradation in other contexts (Lazarou et al.,
2015; Matsumoto, Shimogori, Hattori, & Nukina, 2015; T. D. Nguyen et al., 2019;
Yamada, Dawson, Yanagawa, Iijima, & Sesaki, 2019; Yamada et al., 2018).
U2OS osteosarcoma cells were treated with Bafilomycin A1 for two hours to
inhibit degradation of all cargo delivered to the lysosome and used immunofluorescent
microscopy to determine whether such cargo included mitochondria and p62.
Experiments performed by a Raju Rayavarapu revealed that a minority of the
mitochondrial population (marked by TOMM20) were delivered to LAMP1-positive
lysosomes in the absence of any mitophagy-inducing treatment, and all LAMP1encapsulated mitochondria were co-labeled with p62 (Figure 3-1A, B). In contrast, the
vast majority of LAMP1-negative mitochondria were negative for p62
(Figure 3-1A, 1B). In the absence of Bafilomycin treatment we observed rare instances
of p62-positive mitochondria co-localized with LAMP1 (Figure 3-1A). To determine
whether lysosomal activity detectably limited mitochondrial accumulation under basal
conditions, we used stably expressing mitochondrially targeted mCherry in U2OS cells
(U2OS mito-mCherry cells) and measured mCherry fluorescent intensity per cell by flow
cytometry as a marker of mitochondrial abundance. Short durations of lysosomal
inhibition (< 5 hours) did not detectably increase bulk mitochondrial content per cell,
while longer durations of lysosomal inhibition caused a steady increase of mitochondrial
content over time (Figure 3-1C). Together these results indicate that steady-state
mitochondrial abundance is limited by ongoing delivery of a small subset of p62-labeled
mitochondria to lysosomes for degradation.
Treatment with Bafilomycin A1 increased total protein levels of p62 in a dose
dependent manner, confirming that p62 is continually degraded by the lysosome under
basal conditions (Figure 3-2A). To test whether p62 is required for basal mitochondrial
degradation, I depleted p62 by RNAi and asked whether total mitochondrial content per
cell increased as a result. Multiple independent siRNA oligos targeting p62 caused an
increase in mitochondrial accumulation in U2OS mito-mCherry cells (Figure 3-2B, C).
Similarly, Joseph Miller found that p62 knockout U2OS cells exhibited increased
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Figure 3-1. Basal mitophagy is active in U2OS cells.
(A) U2OS cells were treated with 50 nM bafilomycin A1 for 2 hours to block degradation
of lysosomal contents and analyzed by immunocytochemistry. Representative images are
shown. TOMM20 (Green), p62 (purple), LAMP1 (red), DAPI (blue). Images show
instances of mitochondria (TOMM20) tagged by p62 and surrounded by lysosomes
(LAMP1) designated by white arrows and mitochondria that are not being degraded
designated by yellow arrows. (B) Representative high-resolution STED image of cells
treated as in (A). Note LAMP1-positive lysosomal membrane surrounding (top) or
approaching (bottom) p62-tagged mitochondria. Tomm20 (green), p62 (red), LAMP1
(blue). (C) U2OS mito-mCherry cells were treated with 50nM bafilomycin A1 or vehicle
(DMSO) for the indicated time. Mitochondrial accumulation was measured by flow
cytometry and displayed as percent increase over time.
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Figure 3-2. p62 is an active player in basal mitophagy.
(A) U2OS cells were treated with the indicated concentrations of bafilomycin overnight.
(B) U2OS mito-mCherry cells were transfected with the indicated siRNA oligos or
siControl. (The p62 Si pool contains oligos 1-4). 72 hours later mitochondrial
accumulation was measured by flow cytometry. Mean +/- S.E. of n = 3 independent
experiments is shown; *** p < 0.001; **** p < 0.0001. (C) U2OS cells were transfected
with the indicated siRNAs. 72 hours later lysates were collected and analyzed by western
blot using the indicated antibodies. (D) p62 knockout U2OS cells were generated via
CRISPR/Cas9-mediated genome editing. Cells were stained with 100 nM Mitotracker
Green FM for 30 minutes and mitochondrial accumulation was measured by flow
cytometry. Mean +/- S.E. of n = 7 independent experiments is shown; ** p < 0.01; **** p
< 0.0001. (E) Parental and SQSTM1/p62 knockout U2OS cell lysates were collected and
analyzed by western blot using the indicated antibodies.
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mitochondrial accumulation relative to parental U2OS cells as measured by Mitotracker
Green FM staining (Figure 3-2D, E). Taken together, our data indicate p62 is important
for basal delivery of mitochondria to lysosomes for degradation in the absence of
exogenous damage.
Identification of Novel Mitophagy Regulatory Pathway
To identify novel mitophagy regulatory pathways, we utilized Functional
Signature Ontology (FuSiOn), a method for unbiased identification of functionally
related proteins, to nominate protein kinases from the human genome that function
similarly to p62 under basal conditions (Potts et al., 2013). FuSiOn identified ten kinases
(BMP2K, DCLK3, LIMK2, MAP2K5/MEK5, MAP3K3/MEKK3, ROS1, SIK2,
TAOK2, ULK1, and ULK2) whose depletion mimicked the phenotypic effect of p62
depletion in HCT116 colon cancer cells (Potts et al., 2013). To determine whether any of
these ten candidates promotes basal mitophagy, each kinase was individually depleted in
U2OS mito-mCherry cells and measured the resulting change in average mitochondrial
content per cell. Depletion of seven of the ten kinases caused an increase in
mitochondrial content similar to that caused by depletion of p62 (Figure 3-3A). Next
each kinase was depleted in U2OS GFP-LC3B cells and accumulation of GFP-LC3B as a
marker of nonselective autophagy inhibition was measured. Two candidates (MAP3K3
and MAP2K5) phenocopied p62’s selectivity for mitochondria, demonstrated by the
relatively consistent LC3B levels in addition to the increase in mitochondrial content
(Figure 3-3A). MAP3K3 encodes MEKK3, which activates the MEK5-ERK5 kinase
cascade. MAP2K5 encodes the MEKK3 substrate MEK5 (Figure 3-3B).
On-target efficacy of the siRNA pools directed against MAP3K3/MEKK3 and
MAP2K5/MEK5 was confirmed (Figure 3-4A). Maximum intensity projection images of
U2OS mito-mCherry cells confirmed that the mito-mCherry signal remained localized to
mitochondrial network after depletion of MEKK3 or MEK5 and demonstrated the
accumulation of mitochondrial network in individual cells, supporting the flow
cytometric data (Figure 3-4B). Next, we tested whether pharmacological inhibition of
MEK5 kinase activity could alter mitochondrial abundance using two small molecule
inhibitors of MEK5 (BIX02188 and BIX02189) (Tatake et al., 2008). Both BIX02188
and BIX02189 inhibited MEK5 activity and increased mitochondrial content in a dosedependent manner in varied mammalian cells (Figure 3-5A through D). Given the
structural similarity between the two inhibitors, the off-target activities of BIX02188 and
BIX02189 were measured by Kinome Profiling and determined that the off-target
activities do not overlap (Appendix). This increases the likelihood that the observed
increase in mitochondrial content is due to inhibition of the intended target, MEK5.
Together, these results indicate that MEKK3-MEK5 signaling restrains mitochondrial
accumulation.
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Figure 3-3
Identification of MEKK3/MEK5 as a novel pathway involved in
mitophagy.
(A) Candidate mitophagy-regulating genes identified by FuSiOn were screened by
siRNA-mediated depletion in U2OS mito-mCherry cells and U2OS GFP-LC3B cells.
Depletion of 8 of 11 candidates caused mitochondrial accumulation (red and blue), of
which only 3 exhibited selectivity for mitochondria over the bulk autophagy marker GFPLC3B (red). (B) A model of the MAP3K3 kinase cascade including inhibitors.

Figure 3-4. Confirmation that siRNA knockdown of MEKK3 and MEK5 increase
mitochondrial content.
(A) U2OS cells were transfected with the indicated siRNAs. 72 hours later lysates were
collected and analyzed by western blot using the indicated antibodies. (B) U2OS mitomCherry cells were transfected with the indicated siRNA oligos. 72 hours later cells
were fixed and imaged in z-stacks. Representative maximum intensity projections are
shown.
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Figure 3-5. Pharmacological inhibition of MEK5 increase mitochondrial content.
(A) U2OS cells were treated with vehicle (DMSO) or the indicated concentration of the
MEK5 inhibitor BIX02189 overnight. Lysates were collected and analyzed by western
blot using the indicated antibodies (B) U2OS mito-mCherry cells were treated with
vehicle (DMSO) or the indicated concentration of BIX02189 overnight. Mitochondrial
accumulation was measured by flow cytometry. Mean +/- S.D. of n = 2 independent
experiments is shown. (C) U2OS mito-mCherry cells were treated with vehicle (DMSO)
or the indicated concentration of the MEK5 inhibitor BIX02188 overnight.
Mitochondrial accumulation was measured by flow cytometry. Mean +/- S.D. of n = 3
independent experiments is shown. (D) Mouse embryonic fibroblasts were treated with
vehicle (DMSO) or the indicated concentration of the MEK5 inhibitor BIX02189
overnight.

25

The MEKK3-MEK5-ERK5 Kinase Cascade Prevents Accumulation of Excess
Mitochondria
We proceeded to assay whether the canonical downstream component of this
kinase cascade, ERK5 (encoded by the MAPK7 gene), also plays a role in restraining
mitochondrial accumulation. RNAi-mediated depletion of ERK5 increased the average
mitochondrial content per cell, indicating that ERK5 (like p62, MEKK3, and MEK5)
prevents excess accumulation of mitochondria under basal conditions (Figure 3-6A, B).
A small molecule inhibitor of ERK5, XMD8-92 (Q. Yang et al., 2010), also increased
mitochondrial content in a dose-dependent manner (Figure 3-6C, D). Our collaborators,
Shondra Miller and Sadie Sakura, generated MAPK7/ERK5 knockout U2OS cells using
CRISPR/Cas9 technology, and I analyzed mitochondrial content via western blot and
MitoTracker Green FM staining. In both cases, ERK5 knockout cells exhibited increased
mitochondrial accumulation relative to the parental controls (Figure 3-6E, F). These data
indicate that the canonical MEKK3-MEK5-ERK5 kinase cascade restrains mitochondrial
accumulation under basal conditions.
We asked whether the MEKK3-MEK5-ERK5 kinase cascade promotes
mitochondrial degradation through regulation of p62 protein levels. MEKK3, MEK5, and
p62 all contain PB1 domains, which mediate protein binding with other PB1 domain
containing proteins (Nakamura, Kimple, Siderovski, & Johnson, 2010). We hypothesized
that MEKK3-MEK5-ERK5 pathway inhibition might decrease p62 protein stability, or
alternatively, might reduce p62 expression given that ERK5 is known to translocate to the
nucleus and regulate gene transcription when activated (Drew et al., 2012;
Nithianandarajah-Jones et al., 2012). In either of these cases, a decrease in p62 levels
upon MEKK3-MEK5-ERK5 pathway inhibition could explain why mitochondria
accumulate under those conditions.
However, genetic or pharmacological inactivation of the MEKK3-MEK5-ERK5
kinase cascade induced p62 protein accumulation rather than decrease in abundance,
indicating that MEKK3-MEK5-ERK5 signaling is not required for p62 expression or
stability (Figures 3-5B, 3-6D, and 3-7A). Using immunofluorescent microscopy, we
found that genetic or pharmacological inactivation of the MEKK3-MEK5-ERK5 kinase
cascade caused an increase in the average number of cytoplasmic p62 puncta per cell
(Figure 3-7B through 7E). The punctate accumulation of the selective autophagy adaptor
protein p62 upon inhibition of the MEKK3-MEK5-ERK5 pathway is consistent with the
interpretation that this pathway promotes one or more forms of selective autophagy under
basal conditions.
The MEKK3-MEK5-ERK5 Pathway Is Required for Lysosomal Degradation of
Mitochondria
To determine the underlying cause of increased mitochondrial content observed
upon inhibition of MEKK3-MEK5-ERK5 signaling, I considered and tested three distinct
possibilities: 1) induction of mitochondrial biogenesis; 2) nonselective inhibition of the
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Figure 3-6. Genetic and pharmacological inhibition of downstream component
ERK5 also increases mitochondrial content.
(A)U2OS mito-mCherry cells were transfected with the indicated siRNA oligos targeting.
72 hours later mitochondrial accumulation was analyzed by flow cytometry. Mean +/S.D. of n = 3 independent experiments is shown. (B) U2OS mito-mCherry cells were
transfected with the indicated siRNA oligos. 72 hours later cells were fixed and imaged
in z-stacks. Representative maximum intensity projections are shown. (C, D) U2OS
mito-mCherry cells were treated with vehicle (DMSO) or the indicated concentration of
XMD8-92 overnight. Mitochondrial accumulation was measured by flow cytometry or
western blot, respectively. Mean +/- S.D. of n = 2 independent experiments is shown. (E,
F) Three independent MAPK7/ERK5 knockout U2OS clones were generated by
CRISPR/Cas9. Mitochondrial levels were assessed by western blot using the indicated
antibodies or by Mitotracker Green FM staining and flow cytometry.
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Figure 3-7. Pharmacological and genetic perturbation of the
MEKK3/MEK5/ERK5 pathway cause accumulation of the SAR p62.
(A) U2OS cells were transfected with the indicated siRNAs. 72 hours later lysates were
collected and analyzed by western blot using the indicated antibodies. (B, C) U2OS cells
were treated with the indicated drug at 10 µM overnight. Cells were fixed and stained
with p62 antibody, and then imaged. (D, E) U2OS cells were transfected with the
indicated siRNAs for 72 hours. Cells were fixed and stained with p62 antibody, and then
imaged.
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autophagy-lysosome pathway; and 3) selective inhibition of mitochondrial degradation.
PGC1α is a critical regulator of mitochondrial biogenesis (Jornayvaz & Shulman, 2010),
and increased protein levels and activation of PGC1α leads to an increase in the
transcription of the transcription factors, TFAM, TFB1M, and TFB2M (Villarroya,
Giralt, & Villarroya, 2009). Therefore, if inhibition of MEKK3-MEK5-ERK5 signaling
increases mitochondrial abundance by inducing mitochondrial biogenesis, I should detect
increased expression of PGC1α, TFAM, TFB1M, and TFB2M upon inhibition of the
pathway. RNA-seq confirmed that there was no increase in the mRNA levels of these
major mitochondrial biogenesis related transcription factors upon knockout of ERK5
(Figure 3-8A). I also verified that the protein levels of the master mitochondrial
biogenesis factor PGC1α did not increase upon inhibition of the MEKK3-MEK5-ERK5
pathway. In fact, PGC1α levels decreased upon pharmacological inhibition of MEK5 or
ERK5 (Figure 3-8B), consistent with existing literature reporting a positive role for
ERK5 signaling in promoting mitochondrial biogenesis (W. Liu et al., 2017). Therefore
MEKK3-MEK5-ERK5 signaling does not restrain mitochondrial content by limiting
mitochondrial biogenesis.
Additionally, MEK5-ERK5 signaling is not required for nonselective autophagy
or for general lysosomal function. Wei Zhuang performed a Promega Autophagy Assay,
in which we treated HEK293 cells expressing the HiBiT-LC3 autophagy reporter with a
range of concentrations of DMSO, Bafilomycin A1, Rapamycin, BIX02188, BIX02189,
and XMD8-92 for 24 hours. As expected, Bafilomycin A1 effectively inhibited
nonselective autophagy and Rapamycin effectively induced autophagy across wide dose
ranges, as evidenced by increased (Bafilomycin) or decreased (rapamycin) accumulation
of the HiBiT-LC3 reporter (Figure 3-9A). In contrast, BIX02188, BIX02189, and
XMD8-92 did not inhibit nonselective autophagy even at concentrations as high as 60
µM (Figure 3-9A). We also monitored autophagosome formation and autophagic flux
using U2OS GFP-LC3B cells and observed no disruptions in either process upon
treatment with XMD8-92 (Figure 3-9B, C). Furthermore, I determined that inhibition of
the MEK5-ERK5 pathway does not cause lysosomal deacidification or alter lysosomal
content (Figure 3-9D, E). The combined findings indicate the MEKK3-MEK5-ERK5
kinase cascade restrains mitochondrial accumulation independent of mitochondrial
biogenesis, driving bulk autophagy, or supporting general lysosome function.
Next I questioned whether the MEKK3-MEK5-ERK5 kinase cascade is required
for selective degradation of mitochondria. Therefore, I developed WT and ERK5 KO
U2OS cell lines expressing mitochondrial-targeted monomeric Keima, a pH dependent
fluorescent protein (Kogure, Kawano, Abe, & Miyawaki, 2008; Tantama, Hung, &
Yellen, 2011) to measure the delivery of mitochondria to lysosomes (Figure 2-1). When
targeted to the mitochondria, the pH dependent fluorescence allows us to distinguish
between mitochondria in the cytoplasm (458nm) and mitochondria that are being
degraded in the highly acidic lysosome (561nm) (Biel & Rao, 2018). I found that all three
independent ERK5 knockout clones had significantly less mitochondria in lysosomes
compared to parental cells (Figure 3-10A, B). Furthermore, in parental U2OS mitomKeima cells pharmacological inhibition of ERK5 using XMD8-92 decreased the
amount of basal mitophagy compared to DMSO control (Figure 3-10C). Though
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Figure 3-8. Perturbations of the MEKK3/MEK5/ERK5 pathway do not induce
mitochondrial biogenesis.
(A) RNAseq was performed on parental U2OS cells and two MAPK7/ERK5 knockout
U2OS clones. Expression of selected mRNAs encoding mitochondrial biogenesis genes
is shown. Note that expression of these genes is not elevated in ERK5 knockout cells
relative to parental controls. (B) U2OS cells were treated with vehicle (DMSO) or 10 μM
of the indicated compound overnight. Lysates were collected and analyzed by western
blot with the indicated antibodies.
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Figure 3-9. The MEKK3/MEK5/ERK5 pathway does not promote autophagy
non-selectively.
(A) HEK293 cells stably expressing the HiBiT-LC3 bulk autophagy reporter were treated
with vehicle (DMSO) or the indicated compounds at the indicated concentrations for 24
hours in duplicate. Accumulation of the reporter was measured using the Promega
Autophagy Assay system and normalized to vehicle-treated cells. (B, C) U2OS GFPLC3B cells were treated with DMSO, XMD8-92 (10 μM), Bafilomycin A1 (50 nM), or
XMD8-92 + Bafilomycin A1 for two hours, fixed, stained with DAPI (blue), and imaged
to assess the subcellular localization of GFP-LC3B. Representative images and
quantitation of the number of GFP-LC3B-positive puncta per cell from 19-21 cells per
condition are shown. (D, E) WT and ERK5 KO U2OS cells were plated in a 96 well
plate. Lysosomal content and acidification were measured by staining with LysoTracker
Red and LysoSensor Green respectively. Cells were then imaged, and relative
fluorescence was quantified.
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Figure 3-10. The MEKK3-MEK5-ERK5 pathway is required for lysosomal
degradation of mitochondria.
(A, B) Parental (WT) and ERK5 knockout U2OS cells were transiently transfected with
mitochondrial targeted mKeima. Florescence activated cell sorting was used to select
transfection-positive cells which were then analyzed by fluorescent microscopy.
Representative images and quantification of active mitophagy events are shown. (C) WT
U2OS cells stably transfected with mito-mKeima were treated overnight with vehicle
control or 10 µM XMD8-92. Cells were then collected and analyzed via flow cytometry.
(D) WT U2OS cells transfected with mitochondrial targeted mKeima were treated for 13
hours with DMSO or 10 µM XMD8-92. Three hours before analysis CCCP was added.
Cells were assessed by flow cytometry and mitophagy levels were quantified. Mean +/S.D. of n = 3 independent experiments is shown.
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treatment with mitochondrial uncoupler, CCCP, increased mitophagy in U2OS mitomKeima cells, co-treatment with XMD was not able to mitigate the mitophagy induction
(Figure 3-10D).
We were curious whether the MEKK3-MEK5-ERK5- kinase cascade had a role
in PINK1-parkin mediated mitophagy in high parkin expressing cells. First, we
confirmed that treating YFP-parkin expressing HeLa cells with CCCP did indeed
strongly induce mitophagy (Figure 3-11A, B). When inhibiting the MEKK3-MEK5ERK5 pathway using genetic or pharmacological tools, we did not see mitigated CCCPinduced mitophagy in the presence of ectopic Parkin overexpression in HeLa cells
(Figure 3-11C through E). The combined data indicate the MEKK3-MEK5-ERK5
pathway specifically promotes lysosome-mediated mitochondrial degradation under basal
conditions and is not required for nonspecific bulk autophagy, general lysosome function,
or damage-induced mitophagy nor for restraint of mitochondrial biogenesis.
MEKK3-MEK5-ERK5 Pathway is Required for Differentiation and Mitophagy in
Erythroid Progenitors
Previous studies suggest that ERK5-deficient cells develop altered nucleotide
metabolism, impairing erythropoiesis in mice (Angulo-Ibanez et al., 2015).
Erythropoiesis involves an ordered acquisition and loss of key differentiation markers
(Koulnis et al., 2011). During this process, erythroid progenitors must eliminate their
mitochondria in order to fully mature. We collaborated with Lily Huang at UTSW to
evaluate whether MEK5-ERK5 regulated mitochondrial degradation participates in
erythrocyte maturation (Moras, Lefevre, & Ostuni, 2017). To investigate the possible role
of the MEKK3-MEK5-ERK5 pathway in erythrocyte maturation, Ter119-negative
erythroid progenitors were isolated from murine fetal livers and induced to differentiate
by addition of erythropoietin ex-vivo. We followed the expression of two specific
differentiation markers: CD71, the transferrin receptor, whose expression decreases as
erythroblasts mature, and Ter119, an antigen expressed on cell surfaces of more mature
erythroblasts (Koulnis et al., 2011). BIX02188 or vehicle control (DMSO) were present
throughout the ex-vivo differentiation process. Pharmacological inhibition of MEK5
impaired erythroid differentiation as evidenced by reduced percentages of cells reaching
the most advanced Ter119+CD71low stage of differentiation (Figure 3-12A). Notably,
MEK5 inhibition significantly increased basal mitochondrial content at all stages of
differentiation (Figure 3-12B). As differentiation progressed, both BIX02188-treated
and DMSO-treated cells lost mitochondrial content over time; however, mitochondrial
content was always significantly higher in BIX02188-treated cells relative to DMSOtreated cells at each stage (Figure 3-12B). Similar results were observed when ERK5 was
inhibited using XMD8-92 (Figure 3-13A, B). Erythroid differentiation was also inhibited
by genetic depletion of MEK5 using shRNA (Figure 3-14). Together, these data indicate
that MEK5-ERK5 signaling is required for proper erythroid differentiation and promotes
clearance of mitochondria.
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Figure 3-11. The MEKK3-MEK5-ERK5 pathway is not required for CCCPinduced Parkin-mediated mitophagy.
(A) HeLa YFP-parkin stable cells were transfected with the indicated siRNA for 72 hours
and treated with 10 µM CCCP overnight. Cells were fixed, stained with anti-Tom20 and
DAPI, and imaged. Mitochondrial content was quantified and normalized to DAPI.
(B, C) HeLa YFP-Parkin stable cells were treated with either vehicle control (DMSO) or
10 µM CCCP overnight. Cells were fixed, stained with anti-TOMM20 (red) and DAPI
(blue), and imaged. Individual cells were categorized using TOMM20 fluorescence signal
as exhibiting either mitochondrial retention, partial loss, or complete loss. Quantitation
and representative images are shown. (D, E) HeLa YFP-Parkin stable cells were cotreated with 10 µM CCCP and vehicle control, BIX02189, or XMD8-92 overnight. Cells
were fixed, stained with anti-TOMM20 and DAPI, and imaged. The fraction of
individual cells exhibiting complete mitochondrial loss under each condition is quantified
and representative images are shown.
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Figure 3-12. MEK5 is required for differentiation and mitophagy in erythroid
progenitors.
(A) Pharmacological inhibition of MEK5 impairs erythroid differentiation. Murine
erythroid progenitors were treated with the Mek5 inhibitor BIX02188 (30 μM) or vehicle
control (DMSO) prior to initiation of differentiation. Representative profiles are shown.
(B) Inhibition of MEK5 impairs mitochondrial clearance during erythroid differentiation.
Mitochondrial mass was quantified in Ter119+CD71high and Ter119+CD71low
erythroblasts using median fluorescence intensity (MFI) of MitoTracker Deep Red FM.
The data represent three replicates. ***P < 0.001.
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Figure 3-13. ERK5 is required for differentiation and mitophagy in erythroid
progenitors.
(A) Murine erythroid progenitors were treated with the ERK5 inhibitor XMD8-92 (5μM)
or vehicle control (DMSO) prior to initiation of differentiation. Representative profiles
are shown. (B) Inhibition of ERK5 impairs mitochondrial clearance during erythroid
differentiation. Mitochondrial mass was quantified in Ter119+CD71high and
Ter119+CD71low erythroblasts using median fluorescence intensity (MFI) of
MitoTracker Deep Red FM. The data represent three replicates. * P <0.05; **P < 0.01;
***P < 0.001
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Figure 3-14. Knockdown of MEK5 impairs erythroid differentiation.
MEK5 knockdown impairs differentiation of murine erythroid progenitors. Erythroid
progenitors were transduced with vectors expressing shRNA for MEK5 or control
shRNA prior to erythroid differentiation. Stages of differentiation were identified by
CD71 and Ter119 staining via flow cytometry. Transduced cells, identified by GFP
expression, were gated for analyses. Representative flow cytometric profiles are shown.
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CHAPTER 4.

IDENTIFYING JATROGOSSONE A AS A NOVEL
MITOPHAGY INDUCER

There is a long history of humans using naturally occurring compounds within
microorganisms, plants, or animals for their pharmacological properties. Modern research
can expand on these properties by using natural products as a form of molecular
inspiration for further drug and molecular probe development (Harvey, Edrada-Ebel, &
Quinn, 2015). My focus on natural products is to explore them as a source of new
chemical matter to study mitophagy. To accomplish this, I collaborated with the lab of
Fatima Rivas, which focuses on identifying novel natural products as sources of
anticancer agents, particularly for the treatment of drug resistant cancers.
The Rivas lab conducted a high throughput screen of 100 terrestrial plant extracts
including several from the Euphorbia genus. The genus contains more than 2000 species
(Shi, Su, & Kiyota, 2008) . Plants from the genus Euphorbia have been used as medicinal
plants to treat illnesses such as skin diseases, gonorrhea, migraines, and intestinal
parasites (Shi et al., 2008) . Additionally, several classes of natural products have been
found to be produced by plants in the Euphorbia genus. These natural products have a
wide variety of biological properties including antiproliferative activity, inhibition of
allergic reaction, antimalarial activity, and antimicrobial activity (Hadi et al., 2013; Shi et
al., 2008).
For this study, the Rivas lab extracted secondary metabolites from the plants and
then fractionated and evaluated them for their biological properties against drug sensitive
and resistant leukemia cells as previously described (Hadi et al., 2013). Several fractions
from the extract of Jatropha gossypifolia L. were identified as active hits. Jatrophone was
the most abundant isolated compound (Ling et al., 2019). The Rivas lab and others have
shown the promise of this compound in mechanistic studies; however, its narrow
therapeutic index limits its potential therapeutic value (Bueno et al., 2015; Hadi et al.,
2013). They then identified some related compounds which also displayed biological
properties and focused on the natural product termed Jatrogossone A (JAX), which at the
time had not been reported (Ling et al., 2019).
We went on to show that treatment with Jatrogossone A resulted in increased total
ROS co-localizing in the mitochondria (Ling et al., 2019). Uncontrolled ROS can lead to
damaged mitochondria and loss of membrane potential which will induce mitophagy to
eliminate the effected mitochondria. First, I compared mitochondrial physiology of
Jatrophone treated cells with those of Jatrogossone A treated cells (Figure 4-1). U2OS
cells were treated with DMSO, 1.25µM Jatrophone (JA), or 1.25µM. Jatrogossone A
(JAX). Mitochondria in the JA treated sample display very aberrant morphology while in
the JAX treated sample mitochondria appear to be much healthier.
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Figure 4-1. Treatment with Jatrophone but not Jatrogossone A causes severe
alterations in mitochondrial morphology.
U2OS cells were treated with DMSO, 1.25µM Ja, or 1.25µM JAX for 8 hours. Cells were
the fixed and stained with DAPI (blue) and antibodies for TOMM20 (red), p62 (purple),
and LC3 (green).
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Because of the observed induction of ROS, I next interrogated whether
Jatrogossone A could induce mitophagy events. Mitophagy was measured by using
U2OS cells expressing mitochondrial targeted mKeima. Keima is activated by the 440nm
light at neutral pH (purple) but in the acidic conditions of the lysosome Keima is
activated by 560nm light (green), allowing us to distinguish between cytoplasmic
mitochondria and mitochondria in the last stages of mitophagic degradation. Treatment of
cells with either Jatrophone or Jatrogossone A at 1.25µM and 2.5µM for 8 hr induced
mitophagy (Figure 4-2). However, Jatrogossone A led to higher mitophagy induction at
2.5µM as shown in the relative quantification. Thus, this data strongly suggests that
Jatrogossone A can induce mitophagy and correlate with ROS induction in cancer cell
models. Importantly, the mitophagy-inducing concentration is at least five-fold lower
than the concentration required to induce apoptosis. Hence, this compound is a promising
chemical probe to study mitophagy in cancer

Figure 4-2. Treatment with Jatrogossone A induces mitophagy.
U2OS cells stably expressing mito-mKeima were treated with DMSO, 1.25µM Ja, 2.5µM
Ja, 1.25µM JAX, or 2.5µM JAX for 8 hours. Relative mitophagy levels were quantified
and normalized.
Adapted with permission from Ling T, Lang WH, Craig J, et al. Studies of Jatrogossone
A as a Reactive Oxygen Species Inducer in Cancer Cellular Models. J Nat Prod.
2019;82(5):1301‐1311. https://doi.org/10.1021/acs.jnatprod.8b01087. Copyright (2019)
American Chemical Society.
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CHAPTER 5.

DISCUSSION

Conclusions
Currently, there is substantial interest in the role autophagy plays in maintaining
normal physiology and how dysfunctional mitophagy can lead to or enhance diseases.
Our discovery of the MEKK3-MEK5-ERK5 pathway as a novel mitophagy regulator
could facilitate a deeper understanding of how different mechanisms act to maintain
homeostasis and prevent disease in different tissues. Here, we show that basal
mitochondrial degradation requires p62 and MEKK3-MEK5-ERK5 signaling and is quite
distinct from damage-induced mitophagy, which does not require p62 or MEKK3MEK5-ERK5. One of the key findings of this dissertation is the importance of p62 in
mitophagy under basal conditions. We have found that p62 routinely delivers
mitochondria to lysosomes without the addition of exogenous damage. We also found
that inhibition of autophagy non-specifically with Bafilomycin A1 increases total
mitochondrial load in cells, indicating that mitophagy is an ongoing maintenance process.
Using genetic and pharmacological inhibition of the MEKK3-MEK5-ERK5
pathway, we observed mitochondrial content increase in human cancer cells, mouse
embryonic fibroblasts, and primary erythroid progenitor cells isolated from the murine
fetal liver. This suggests that MEKK3-MEK5-ERK5 restrains mitochondrial
accumulation in diverse cells and tissues. We also observed an increase in the levels of
mitophagy receptor protein p62 after pharmacological or genetic inhibition of MEKK3MEK5-ERK5 signaling. I confirmed that inhibition of pathway activity results in
decreased lysosome-dependent degradation of mitochondria using mitochondrial targeted
mKeima, without affecting lysosome acidification or non-selective bulk-autophagy levels
in the cell. Taken together, it was found that the MEKK3-MEK5-ERK5 pathway
promotes mitophagy without the addition of exogenous mitochondrial damage, which
could have great implication on studying mitophagy in the context of development and
disease.
We also sought to investigate whether developmentally programmed
mitochondrial degradation in the erythrocyte lineage required MEK5-ERK5 signaling as
a well-established model of mitochondrial clearance in the absence of exogenous
damage. Although impaired maturation of erythrocytes upon MEK5 or ERK5 inhibition
precluded full assessment of the impact on mitochondrial turnover, the mitochondrial
content was increased at each stage of erythroid maturation in MEK5-ERK5 inhibited
cells. Taken together with the lack of a requirement for MEKK3-MEK5-ERK5 signaling
in CCCP-induced mitophagy, it appears that the MEKK3-MEK5-ERK5 pathway may be
solely designated for basal mitochondrial clearance. It is also possible that MEKK3MEK5-ERK5 signaling may be required for induction of mitochondrial degradation by
other stimuli, such as statin treatment, hypoxia, or forced metabolic switch from
glycolytic metabolism to oxidative phosphorylation (Andres et al., 2014; L. Liu et al.,
2012; Sin et al., 2016; Wilkinson, Sidaway, & Cross, 2018). These questions remain to be
addressed in future work.
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Future Directions
Whether MEKK3-MEK5-ERK5 signaling controls mitochondrial degradation by
directly or indirectly regulating p62 remains to be determined, although we have ruled
out the possibility that MEKK3-MEK5-ERK5 signaling is required for p62 expression or
stability. Direct interactions between the PB1 domain of p62 and the PB1 domains of
MEKK3 and MEK5 have been reported, providing a potential means for direct regulation
of p62 by the MEKK3-MEK5-ERK5 kinase cascade (Lamark et al., 2003; Nakamura et
al., 2010).
While MEKK3-MEK5-ERK5 signaling has been implicated in many aspects of
mammalian development and disease, it is also the most newly discovered MAP kinase
pathway, and much work needs to be done to fully understand how the MEKK3-MEK5ERK5 kinase cascade is acting. It will be interesting to determine whether any of these
previously identified roles for the ERK5 pathway in development, physiology, or disease
represent an underlying role for mitochondrial degradation. For example, ERK5 signaling
is well established to play an anti-apoptotic role, and mitochondria harbor several proapoptotic molecules including cytochrome c, Smac/DIABLO, and AIF (Adrain, Creagh,
& Martin, 2001; Baechler, Bloemberg, & Quadrilatero, 2019; Nithianandarajah-Jones et
al., 2012). It is possible that active ERK5 signaling antagonizes autophagy in part through
elimination of pro-apoptotic molecules through delivery of mitochondria to lysosomes for
degradation. These and other interesting hypotheses arising from our current work remain
to be tested in future studies.
Additionally, we helped discover a novel mitophagy inducing drug, Jatrogossone
A. Recently, there has been interest in using pharmacological screens to identify novel
chemical modulators that might be used to promote the efficient removal of damaged
mitochondria in hopes of restoring the cell to metabolic homeostasis. Mitochondrial
uncouplers, like CCCP, have been widely used to induce mitochondrial removal via the
activation of the PINK1/Parkin pathway (Geisler et al., 2010; Narendra et al., 2008;
Okatsu et al., 2010). However, we have shown that CCCP does not effectively induce all
mitophagy pathways, therefore, it is useful to have several tools that could be used to
stimulate different mechanisms of mitophagy. Next, we could expand these techniques to
create a larger scale screening process to search for new natural products to induce
mitophagy.
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APPENDIX. BIX02188 AND BIX02189 KINOME PROFILING

Kinase
Abl (H396P) (h)
Abl (M351T)(h)
Abl (Q252H) (h)
Abl(h)
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Abl(T315I)(h)
Abl(Y253F)(h)
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ALK4(h)
AMPKα1(h)
AMPKα2(h)
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Arg(m)
ARK5(h)
ASK1(h)
Aurora-A(h)
Aurora-B(h)
Aurora-C(h)
Axl(h)
Blk(h)
Blk(m)
Bmx(h)
BRK(h)
BrSK1(h)
BrSK2(h)
BTK(h)
BTK(R28H)(h)
CaMKI(h)
CaMKIIβ(h)
CaMKIIγ(h)
CaMKIIδ(h)
CaMKIV(h)
CaMKIδ(h)
CDK1/cyclinB(h)
CDK2/cyclinA(h)
CDK2/cyclinE(h)
CDK3/cyclinE(h)
CDK5/p25(h)
CDK5/p35(h)

BIX02188
0.0043
0.043
µM
µM
110
96
96
96
98
93
102
113
93
99
97
99
97
97
95
104
106
114
97
104
111
118
101
106
110
107
104
99
96
102
123
97
115
107
112
101
114
103
113
116
104
99
90
102
105
104
111
108
110
109
100
108
111
96
101
103
114
110
112
103
102
98
112
115
109
116
109
108
99
106
100
101
95
99
111
111
103
101
101
99

54

BIX02189
0.0015
0.015
µM
µM
109
109
105
102
96
107
105
103
103
102
100
99
109
105
109
97
106
105
108
99
109
1
105
113
118
116
101
100
107
92
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129
117
111
113
123
106
92
113
111
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105
110
113
102
98
110
113
102
95
107
105
110
102
89
86
102
96
109
111
100
96
113
96
100
108
109
114
96
94
103
99
92
95
115
95
102
103
106
98

CDK6/cyclinD3(h)
CDK7/cyclinH/MAT1(h)
CDK9/cyclin T1(h)
CHK1(h)
CHK2(h)
CHK2(I157T)(h)
CHK2(R145W)(h)
CK1(y)
CK1γ1(h)
CK1γ2(h)
CK1γ3(h)
CK1δ(h)
CK2(h)
CK2α2(h)
cKit(D816H)(h)
cKit(D816V)(h)
cKit(h)
cKit(V560G)(h)
cKit(V654A)(h)
CLK2(h)
CLK3(h)
c-RAF(h)
CSK(h)
cSRC(h)
DAPK1(h)
DAPK2(h)
DCAMKL2(h)
DDR2(h)
DMPK(h)
DRAK1(h)
DYRK2(h)
eEF-2K(h)
EGFR(h)
EGFR(L858R)(h)
EGFR(L861Q)(h)
EGFR(T790M)(h)
EGFR(T790M,L858R)(h)
EphA1(h)
EphA2(h)
EphA3(h)
EphA4(h)
EphA5(h)
EphA7(h)
EphA8(h)
EphB1(h)
EphB2(h)

105
100
102
99
98
115
109
105
104
107
91
106
102
100
81
104
104
86
85
95
104
102
102
111
105
107
124
127
107
100
94
102
115
109
105
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94
108
127
96
110
98
103
102
117
98
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110
97
101
100
100
109
97
96
102
105
105
103
105
98
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96
100
34
53
92
109
98
102
98
110
104
111
121
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109
107
104
105
104
94
109
98
104
100
108
107
95
104
107
100
105
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101
101
106
111
121
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99
110
95
102
100
104
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93
104
113
113
94
98
108
102
97
110
110
112
114
120
119
111
102
98
101
104
103
107
105
110
117
113
110
99
101
107
107
94

105
97
112
103
108
109
98
101
108
98
105
105
98
94
79
100
106
92
87
99
103
105
106
99
99
102
102
118
102
117
107
99
102
98
107
96
98
107
119
103
102
105
99
102
105
91

EphB3(h)
EphB4(h)
ErbB4(h)
FAK(h)
Fer(h)
Fes(h)
FGFR1(h)
FGFR1(V561M)(h)
FGFR2(h)
FGFR2(N549H)(h)
FGFR3(h)
FGFR4(h)
Fgr(h)
Flt1(h)
Flt3(D835Y)(h)
Flt3(h)
Flt4(h)
Fms(h)
Fms(Y969C)(h)
Fyn(h)
GCK(h)
GRK5(h)
GRK6(h)
GRK7(h)
GSK3α(h)
GSK3β(h)
Haspin(h)
Hck(h)
Hck(h) activated
HIPK1(h)
HIPK2(h)
HIPK3(h)
IGF-1R(h)
IGF-1R(h), activated
IKKα(h)
IKKβ(h)
IR(h)
IR(h), activated
IRAK1(h)
IRAK4(h)
IRR(h)
Itk(h)
JAK2(h)
JAK3(h)
JNK1α1(h)
JNK2α2(h)

104
98
114
102
112
85
112
106
103
105
107
105
94
110
105
84
106
106
100
88
124
99
97
95
92
94
106
96
100
115
112
101
102
110
113
111
101
107
106
95
112
99
112
101
108
109
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100
100
112
103
104
99
108
98
102
102
101
110
105
109
105
88
101
100
78
64
100
103
104
93
93
88
92
74
82
114
105
108
95
115
106
109
104
110
103
110
132
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114
106
103
110

103
107
123
101
112
110
108
97
97
109
107
101
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118
96
93
108
102
101
104
102
103
102
114
95
86
102
101
102
112
105
105
100
113
104
101
104
111
102
100
120
107
97
103
95
99

99
104
110
98
110
105
103
101
98
103
109
102
99
102
109
107
94
97
84
93
99
97
100
99
95
91
100
87
105
102
112
107
99
101
113
104
90
104
110
112
119
95
111
97
97
102

JNK3(h)
KDR(h)
Lck(h)
Lck(h) activated
LIMK1(h)
LKB1(h)
LOK(h)
Lyn(h)
Lyn(m)
MAPK1(h)
MAPK2(h)
MAPK2(m)
MAPKAP-K2(h)
MAPKAP-K3(h)
MARK1(h)
MEK1(h)
MELK(h)
Mer(h)
Met(D1246H)(h)
Met(D1246N)(h)
Met(h)
Met(M1268T)(h)
Met(Y1248C)(h)
Met(Y1248D)(h)
Met(Y1248H)(h)
MINK(h)
MKK4(m)
MKK6(h)
MKK7β(h)
MLCK(h)
MLK1(h)
Mnk2(h)
MRCKα(h)
MRCKβ(h)
MSK1(h)
MSK2(h)
MSSK1(h)
MST1(h)
MST2(h)
MST3(h)
mTOR(h)
mTOR/FKBP12(h)
MuSK(h)
NEK11(h)
NEK2(h)
NEK3(h)

102
100
100
106
102
101
98
95
93
101
105
108
99
99
105
118
93
110
108
92
122
99
105
99
95
110
122
92
137
99
96
104
113
99
108
125
105
107
104
88
104
92
88
103
100
111

57

107
102
85
97
103
96
94
100
95
106
105
117
93
94
105
123
77
109
100
100
133
115
98
97
93
110
103
71
137
106
104
101
115
108
106
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110
103
117
109
95
105
109
111
91
107

107
103
103
111
107
104
109
99
93
106
101
114
102
100
110
117
85
102
98
100
107
101
111
107
102
106
126
91
132
98
107
97
106
102
105
116
99
109
101
95
101
97
95
100
99
125

100
113
89
103
97
104
96
92
98
102
96
106
100
93
113
121
82
102
102
99
144
109
100
107
101
112
114
94
128
94
93
105
104
105
103
120
95
100
106
99
95
90
82
95
94
125

NEK6(h)
NEK7(h)
NLK(h)
p70S6K(h)
PAK2(h)
PAK4(h)
PAK5(h)
PAK6(h)
PAR-1Bα(h)
PASK(h)
PDGFRα(D842V)(h)
PDGFRα(h)
PDGFRα(V561D)(h)
PDGFRβ(h)
PDK1(h)
PEK(h)
PhKγ2(h)
PI3 Kinase
(p110a(E542K)/p85a)(h)
PI3 Kinase
(p110a(E542K)/p85a)(m)
PI3 Kinase
(p110a(E545K)/p85a)(h)
PI3 Kinase
(p110a(E545K)/p85a)(m)
PI3 Kinase
(p110a(H1047R)/p85a)(h)
PI3 Kinase
(p110a(H1047R)/p85a)(m)
PI3 Kinase (p110a/p65a)(h)
PI3 Kinase (p110a/p65a)(m)
PI3 Kinase (p110a/p85a)(h)
PI3 Kinase (p110a/p85a)(m)
PI3 Kinase (p110b/p85a)(h)
PI3 Kinase (p110b/p85a)(m)
PI3 Kinase (p110b/p85b)(m)
PI3 Kinase (p110d/p85a)(h)
PI3 Kinase (p110d/p85a)(m)
PI3 Kinase (p120g)(h)
PI3KC2a(h)
PI3KC2g(h)
Pim-1(h)
Pim-2(h)
Pim-3(h)
PIP4K2a(h)
PIP5K1a(h)

103
119
98
101
96
97
128
102
105
105
96
104
94
114
106
101
102

112
112
97
110
109
103
121
104
105
105
73
97
55
101
111
102
110

101
111
105
104
96
97
113
103
104
92
98
88
101
127
105
100
117

100
110
96
118
88
103
119
104
103
105
88
108
103
130
103
100
113

103

102

102

103

102

101

103

103

99

102

100

61

99

100

98

97

104

102

102

101

101
103
98
101
101
97
100
103
102
106
100
103
99
109
94
99
107
103

100
101
99
99
105
96
100
101
104
104
92
96
97
101
93
104
104
98

102
101
97
99
99
105
105
102
102
103
101
98
98
106
110
99
98
100

101
99
99
101
104
101
101
107
102
100
107
103
100
104
103
97
101
100
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PIP5K1g(h)
PKA(h)
PKBα(h)
PKBβ(h)
PKBγ(h)
PKCα(h)
PKCβI(h)
PKCβII(h)
PKCγ(h)
PKCδ(h)
PKCε(h)
PKCζ(h)
PKCη(h)
PKCθ(h)
PKCι(h)
PKCμ(h)
PKD2(h)
PKG1α(h)
PKG1β(h)
Plk1(h)
Plk3(h)
PRAK(h)
PRK2(h)
PrKX(h)
PTK5(h)
Pyk2(h)
Ret (V804L)(h)
Ret(h)
Ret(V804M)(h)
RIPK2(h)
ROCK-I(h)
ROCK-II(h)
ROCK-II(r)
Ron(h)
Ros(h)
Rse(h)
Rsk1(h)
Rsk1(r)
Rsk2(h)
Rsk3(h)
Rsk4(h)
SAPK2a(h)
SAPK2a(T106M)(h)
SAPK2b(h)
SAPK3(h)
SAPK4(h)

96
108
104
106
117
103
104
107
100
109
103
110
110
109
103
103
101
107
109
106
97
97
108
120
108
96
99
101
102
97
94
110
105
103
110
101
98
107
95
110
108
109
95
109
99
123
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90
109
107
98
116
102
114
107
102
97
103
100
109
107
101
109
102
93
113
115
95
101
105
126
122
99
90
114
101
103
104
112
107
115
106
104
106
101
100
108
110
105
97
96
103
110

98
101
107
107
104
101
110
101
100
110
102
106
96
112
94
111
116
110
100
110
93
100
113
122
103
105
103
109
106
96
108
109
115
112
104
110
101
109
109
113
108
112
106
95
109
120

93
104
108
107
107
105
119
101
88
105
113
104
98
107
109
105
117
108
120
107
94
90
107
120
99
99
96
98
106
95
105
105
110
102
99
97
98
115
107
108
104
107
103
105
102
120

SGK(h)
SGK2(h)
SGK3(h)
SIK(h)
Snk(h)
Src(1-530)(h)
Src(T341M)(h)
SRPK1(h)
SRPK2(h)
STK33(h)
Syk(h)
TAK1(h)
TAO1(h)
TAO2(h)
TAO3(h)
TBK1(h)
Tec(h) activated
TGFBR1(h)
Tie2 (h)
Tie2(R849W)(h)
Tie2(Y897S)(h)
TLK2(h)
TrkA(h)
TrkB(h)
TSSK1(h)
TSSK2(h)
Txk(h)
ULK2(h)
ULK3(h)
VRK2(h)
WNK2(h)
WNK3(h)
Yes(h)
ZAP-70(h)
ZIPK(h)

96
92
111
108
116
97
97
107
105
106
100
104
104
119
109
109
113
103
93
94
93
106
112
130
106
115
94
100
100
95
130
98
102
115
107
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99
100
122
102
113
91
106
109
105
110
101
105
112
97
106
111
102
100
101
104
96
104
105
141
102
120
92
98
101
99
122
109
99
115
106

93
98
108
102
121
90
101
103
105
103
112
109
108
120
112
102
94
106
96
97
94
109
112
148
104
111
100
95
101
107
119
102
102
110
112

101
108
110
104
109
99
98
104
106
104
107
101
103
106
100
103
104
101
105
99
93
100
108
106
4
110
96
93
103
99
106
97
96
105
117
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